Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR:GET-1 rituximab for acute antibody-mediated rejection after kidney transplantation
2018-002882-20Phase 3Unknown
- Sponsor
- Imperial College London
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in antibody mediated rejection (AMR) comparing Standard of care with Rituximab plus standard of care (2 arms). Primary endpoint: Allograft survival. Status: unknown.
02
Drugs
rituximab
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on 2018-002882-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002882-20.